Thrombopoietin

REFERENCES

• Wright J. H. The Origin and Nature of Blood Plates. Boston Med. Surg. J. 1906; 154: 643
   Google Scholar
• Metcalf D., Burgess A. W., Johnson G. R., et al. In Vitro Actions on Hematopoietic Cells of Recombinant Murine GM-CSF Purified After Production in Escherichia coli:Comparison with Purified Native GM-CSF. J. Cell Physiol. 1986; 128: 421–431
   PubMed Web of Science ®Google Scholar
• Metcalf D., Begley C. G., Johnson G. R., Nicola N., Lopez A. F., Williamson D. J. Effects of Purified Bacterially Synthesized Murine Multi-CSF (IL-3) on Hematopoiesis in Normal Adult Mice. Blood 1986; 68: 46–57
   PubMed Web of Science ®Google Scholar
• Metcalf D., Begley C. G., Williamson D. J, et al. Hemopoietic Responses in Mice Injected with Purified Recombinant Murine GM-CSF. Exp. Hematol. 1987; 15: 1–9
   PubMed Web of Science ®Google Scholar
• Furman W. L., Luo X., Marina N., Garrison L., Pratt C. B., Meyer W. H. Comparison of Cytokines in Children with Recurrent Solid Tumors Treated with Intensive Chemotherapy. J. Pediatr. Hematol. Oncol. 1998; 20: 62–68
   PubMed Web of Science ®Google Scholar
• Kimura H., Ishibashi T., Shikama Y., et al. Interleukin-1 Beta (IL-1 Beta) Induces Thrombocytosis in Mice: Possible Implication of IL-6. Blood 1990; 76: 2493–2500
   PubMed Web of Science ®Google Scholar
• Robb L., Hilton D. J., Willson T. A., Begley C. G. Structural Analysis of the Gene Encoding the Murine Interleukin-11 Receptor Alpha Chain and a Related Locus. J. Biol. Chem. 1996; 271: 13754–13761
   PubMed Web of Science ®Google Scholar
• Douglas A. M., Goss G. A., Sutherland R. L., et al. Expression and Function of Members of the Cytokine Receptor Superfamily on Breast Cancer Cells. Oncogene 1997; 14: 661–669
   PubMed Web of Science ®Google Scholar
• Robb L., Hilton D., Brook-Carter P. T., Begley G. C. Identification of a Second Murine Interleukin-11 Receptor -chain gene (IL-11Rα2) with a restricted pattern of expression. Genomics 1997; 40: 387–394
   PubMed Web of Science ®Google Scholar
• Kelemen E., Csehati I., Tanos B. Demonstration and Some Properties of Human Thrombopoietin in Thrombocythemic Sera. Acta Haematol. 1958; 20: 350–355
   PubMedGoogle Scholar
• Hill R. J., Levin J. Regulators of Thrombopoiesis: Their Biochemistry and Physiology. Blood Cells 1989; 15: 141–166
   PubMedGoogle Scholar
• Mazur E. M. Megakaryocytopoiesis and Platelet Production: A Review. Exp. Hematol. 1987; 15: 340–350
   PubMed Web of Science ®Google Scholar
• Bartley T. D., Bogenberger J., Hunt P., et al. Identification and Cloning of a Megakaryocyte Growth and Development Factor That Is a Ligand for the Cytokine Receptor mpl. Cell 1994; 77: 1117–1124
   PubMed Web of Science ®Google Scholar
• Lok S., Kaushansky K., Holly R. D., et al. Cloning and Expression of Murine Thrombopoietin cDNA and Stimulation of Platelet Production In Vivo. Nature 1994; 369: 565–568
   PubMed Web of Science ®Google Scholar
• de Sauvage F. J., Hass P. E., Spencer S. D., et al. Stimulation of Megakaryopoiesis and Thrombopoiesis by the c-mpl Ligand. Nature 1994; 369: 533–538
   PubMed Web of Science ®Google Scholar
• Sohma Y., Akahori H., Seki N., et al. Molecular Cloning and Chromosomal Localization of the Human Thrombopoietin Gene. FEBS Lett. 1994; 353: 57–61
   PubMed Web of Science ®Google Scholar
• Kuter D. J., Beeler D. L., Rosenberg R. D. The Purification of Megapoietin. A Physiological Regulator of Megakaryocyte Growth and Platelet Production. Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 11104–11108
   PubMed Web of Science ®Google Scholar
• de Sauvage F. J., Carver-Moore K., Luoh S-M., et al. Physiological Regulation of Early and Late Stages of Megakaryocytopoiesis by Thrombopoietin. J. Exp. Med. 1996; 183: 651–656
   PubMed Web of Science ®Google Scholar
• Gurney A. L., Carver-Moore K., de Sauvage F. J., Moore M. A. Thrombocytopenia in c-mpl-Deficient Mice. Science 1994; 265: 1445–1447
   PubMed Web of Science ®Google Scholar
• Alexander W. S., Roberts A. W., Nicola N. A., Li R., Metcalf D. Deficiencies in Progenitor Cells of Multiple Hematopoietic Lineages and Defective Megakaryopoiesis in Mice Lacking the Thrombopoietin Receptor c-mpl. Blood 1996; 87: 2162–2170
   PubMed Web of Science ®Google Scholar
• Gainsford T., Roberts A. W., Kimura S., et al. Cytokine Production and Function in c-mpl-Deficient Mice: No Physiologic Role for Interleukin-3 in Residual Megakaryocyte and Platelet Production. Blood 1998; 91: 2745–2752
   PubMed Web of Science ®Google Scholar
• Gainsford T., Nandurkar H. H., Metcalf D., Robb L., Begley C. G., Alexander W. S. The Residual Megakaryocyte and Platelet Production in c-mpl-Deficient Mice Is Not Dependent on the Actions of Interleukin-6, Interleukin-11 or Leukemia Inhibitory Factor. Blood 2000; 95: 528–534
   PubMed Web of Science ®Google Scholar
• Basser R. L., Rasko J. E.J., Clarke K., et al. Thrombopoietic Effects of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) in Patients with Advanced Cancer. Lancet 1996; 348: 1279–1281
   PubMed Web of Science ®Google Scholar
• Vadhan-Raj S., Murray L. J., Bueso-Ramos C., et al. Stimulation of Megakaryocyte and Platelet Production by a Single Dose of Recombinant Human Thrombopoietin in Patients with Cancer. Ann. Intern. Med. 1997; 126: 673–681
   PubMed Web of Science ®Google Scholar
• Fanucchi M., Glaspy J., Crawford J., et al. Effects of Polyethylene Glycol-Conjugated Recombinant Human Megakaryocyte Growth and Development Factor on Platelet Counts After Chemotherapy for Lung Cancer. N. Engl. J. Med. 1997; 336: 404–409
   PubMed Web of Science ®Google Scholar
• Rasko J. E.J., Basser R. L., Boyd J., et al. Multilineage Mobilization of Peripheral Blood Progenitor Cells in Humans Following Administration of PEG-rHuMGDF. Br. J. Haematol. 1997; 97: 871–880
   PubMed Web of Science ®Google Scholar
• Rasko J. E., O'Flaherty E., Begley C. G. Mpl Ligand (MGDF) Alone and in Combination with Stem Cell Factor (SCF) Promotes Proliferation and Survival of Human Megakaryocyte, Erythroid and Granulocyte/Macrophage Progenitors. Stem Cells 1997; 15: 33–42
   PubMed Web of Science ®Google Scholar
• Ku H., Yonemura Y., Kaushansky K., Ogawa M. Thrombopoietin, the Ligand for the Mpl Receptor, Synergizes with Steel Factor and Other Early Acting Cytokines in Supporting Proliferation of Primitive Hematopoietic Progenitors of Mice. Blood 1996; 87: 4544–4551
   PubMed Web of Science ®Google Scholar
• Sitnicka E., Lin N., Priestley G. V., et al. The Effect of Thrombopoietin on the Proliferation and Differentiation of Murine Hematopoietic Cells. Blood 1996; 87: 4998–5005
   PubMed Web of Science ®Google Scholar
• Carver-Moore K., Broxmeyer H. E., Luoh S-M., et al. Low Levels of Erythroid and Myeloid Progenitors in Thrombopoietin and c-mpl-Deficient Mice. Blood 1996; 88: 803–808
   PubMed Web of Science ®Google Scholar
• Scott C. L., Nandurkar H. H., Mansfield R., Alexander W. S., Begley C. G. Thrombopoietin Signaling Is Required for In-Vivo Expansion of IL-11 Responsive Hematopoietic Progenitor Cells in the Steady State. Exp. Hematol. 2001; 29: 138–145
   PubMed Web of Science ®Google Scholar
• Kimura S., Roberts A. W., Metcalf D., Alexander W. S. Hematopoietic Stem Cell Deficiencies in Mice Lacking c-Mpl, the Receptor for Thrombopoietin. Proc. Natl. Acad. Sci. U.S.A. 1998; 95: 1195–1200
   PubMed Web of Science ®Google Scholar
• Basser R. L., Rasko J. E.J., Clarke K., et al. Randomised, Blinded, Placebo-Controlled Phase I Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) with Filgrastim After Dose-Intensive Chemotherapy in Patients with Advanced Cancer. Blood 1997; 89: 3118–3128
   PubMed Web of Science ®Google Scholar
• Crawford J., Glaspy J., Belani C., et al. A Randomized, Placebo-Controlled, Blinded, Dose Scheduling Trial of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHMGDF) with Filgrastim Support in Non-Small Cell Lung Cancer (NSCLC) Patients Treated with Paclitaxel and Carboplatin During Multiple Cycles of Chemotherapy. Proc. Am. Soc. Clin. Oncol. 1998; 17: 73a, (abstract)
   Google Scholar
• Moskowitz C., Nimer S., Gabrilove J., et al. A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding, Efficacy and Safety Study of PEG-rHuMGDF (M) in Non-Hodgkin's Lymphoma (NHL) Patients (pts) Treated with ICE (Ifosfamide, Carboplatin and Etoposide). Proc. Am. Soc. Clin. Oncol. 1998; 17: 76a, abstract
   Google Scholar
• Archimbaud E., Ottmann O. G., Yin J. A.L., et al. A Randomized, Double-Blind, Placebo-Controlled Study with Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) as an Adjunct to Chemotherapy for Adults with De Novo Acute Myeloid Leukemia. Blood 1999; 94: 3694–3701
   PubMed Web of Science ®Google Scholar
• Beveridge R., Schuster M., Waller E., et al. Randomized, Double-Blind, Placebo-Controlled Trial of Pegylated Recombinant Human Growth and Development Factor (PEG-rHUMGDF) in Breast Cancer Patients (Pts) Following Autologous Bone Marrow Transplantation (ABMT). Blood 1997; 90(suppl 1)580a, abstract
   Google Scholar
• Bolwell B., Vredenburgh J., Overmoyer B., et al. Safety and Biologic Effect of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) in Breast Cancer Patients Following Autologous Peripheral Blood Progenitor Cell Transplantation (PBPC). Blood 1997; 90(suppl 1)171a, abstract
   Google Scholar
• Glaspy J., Vredenburgh J., Demetri G. D., et al. Effects of PEGylated Recombinant Human Megakaryocyte Growth and Development Factor (PEG-rHuMGDF) Before High-Dose Chemotherapy (HDC) with Peripheral Blood Progenitor Cell (PBPC) Support. Blood 1997; 90(suppl 1)580a, abstract
   Google Scholar
• Murray L. J., Luens K. M., Estrada M. E., et al. Thrombopoietin Mobilizes CD34+ Cell Subsets into Peripheral Blood and Expands Multilineage Progenitors in Bone Marrow of Cancer Patients with Normal Hematopoiesis. Exp. Hematol. 1998; 26: 207–216
   PubMed Web of Science ®Google Scholar
• Chen J. C., Herceg-Harjacek L., Groopman J. E., Grabarek J. Regulation of Platelet Activation In Vitro by the c-Mpl Ligand, Thrombopoietin. Blood 1995; 86: 4054–4062
   PubMed Web of Science ®Google Scholar
• Kojima H., Hamazaki Y., Nagata Y., Todokoro K., Nagasawa T., Abe T. Modulation of Platelet Activation In Vitro by Thrombopoietin. Thromb. Haemost. 1995; 74: 1541–1545
   PubMed Web of Science ®Google Scholar
• Ezumi Y., Takayama H., Okuma M. Thrombopoietin, c-Mpl Ligand, Induces Tyrosine Phosphorylation of Tyk2, JAK2, and STAT3, and Enhances Agonists-Induced Aggregation in Platelets In Vitro. FEBS Lett. 1995; 374: 48–52
   PubMed Web of Science ®Google Scholar
• O'Malley C. J., Rasko J. E.J., Basser R. L., et al. Administration of Pegylated Recombinant Human Megakaryocyte Growth and Development Factor to Humans Stimulates the Production of Functional Platelets That Show No Evidence of In Vivo Activation. Blood 1996; 88: 3288–3298
   PubMed Web of Science ®Google Scholar
• Choi E. S., Hokom M. M., Chen J. L., et al. The Role of Megakaryocyte Growth and Development Factor in Terminal Stages of Thrombopoiesis. Br. J. Haematol. 1996; 95: 227–233
   PubMed Web of Science ®Google Scholar
• Basser R. L., O'Flaherty E., Nichol J., et al. Development of Pancytopenia in Association with Neutralizing Antibodies to Thrombopoietin After Multicycle Chemotherapy Supported by Megakaryocyte Growth and Development Factor. Submitted for publication. 1999
   Google Scholar
• Elwood N. J., Zogos H., Pereria D., Dick J. E., Begley C. G. Enhanced Megakaryocyte and Erythroid Development from Normal Human CD34 Positive Cells: Consequences of Enforced Expression of SCL. Blood 1998; 91: 3756–3765
   PubMed Web of Science ®Google Scholar
• Begley C. G., Green A. R. The SCL Gene: From Case Report to Critical Hematopoietic Regulator. Blood 1999; 93: 2760–2770
   PubMed Web of Science ®Google Scholar
• Shivdasani R. A., Fujiwara Y., McDevitt M. A., Orkin S. H. A Lineage-Selective Knockout Establishes the Critical Role of Transcription Factor GATA-1 in Megakaryocyte Growth and Platelet Development. EMBO J. 1997; 16: 3965–3973
   PubMed Web of Science ®Google Scholar
• Vyas P., Ault K., Jackson C. W., Orkin S. H., Shivdasani R. A. Consequences of GATA-1 Deficiency in Megakaryocytes and Platelets. Blood 1999; 93: 2867–2875
   PubMed Web of Science ®Google Scholar
• Shivdasani R. A., Rosenblatt M. F., Zucker-Franklin D., et al. Transcription Factor NF-E2 is Required for Platelet Formation Independent of the Actions of Thrombopoietin/MGDF in Megakaryocyte Development. Cell 1995; 81: 695–704
   PubMed Web of Science ®Google Scholar
• Kimura T., Kaburaki H., Miyamoto S., Katayama J., Watanabe Y. Discovery of a Novel Thrombopoietin Mimic Agonist Peptide. J. Biochem. (Tokyo) 1997; 122: 1046–1051
   PubMed Web of Science ®Google Scholar
• Cwirla S. E., Balasubramanian P., Duffin D. J., et al. Peptide Agonist of the Thrombopoietin Receptor as Potent as the Natural Cytokine. Science 1997; 276: 1696–1699
   PubMed Web of Science ®Google Scholar
• De Serres M., Ellis B., Dillberger J. E., et al. Immunogenicity of Thrombopoietin Mimetic Peptide GW395058 in BALB/c Mice and New Zealand White Rabbits: Evaluation of the Potential for Thrombopoietin Neutralizing Antibody Production in Man. Stem Cells 1999; 17: 203–209
   PubMed Web of Science ®Google Scholar
• De Serres M., Yeager R. L., Dillberger J. E., et al. Pharmacokinetics and Hematological Effects of the PEGy lated Thrombopoietin Peptide Mimetic GW395058 in Rats and Monkeys After Intravenous or Subcutaneous Administration. Stem Cells 1999; 17: 316–326
   PubMed Web of Science ®Google Scholar